Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | AMD1 | P17707 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867517 | 0.82 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBHIF1A | |
| SCHEMBL18009769 | 0.81 | PI4KA (0.34) | PI4KAPI4K2BPI4K2API4KBHIF1A | |
| SCHEMBL866642 | 0.79 | RXFP1 (0.36) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL18026290 | 0.79 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL3301771 | 0.79 | HIF1A (0.58) | PI4KAPI4K2BPI4K2API4KBHIF1A | |
| SCHEMBL29444521 | 0.78 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL18009718 | 0.76 | RXFP1 (0.31) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL866604 | 0.76 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBHIF1A | |
| SCHEMBL10149282 | 0.76 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBHIF1A | |
| SCHEMBL11997788 | 0.76 | HIF1A (0.47) | PI4KAPI4K2BPI4K2API4KBHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262057-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3262057-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | PI4KA 769/4885PI4K2B 1095/4885PI4K2A 903/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PI4KA 989/4885PI4K2B 1184/4885PI4K2A 1232/4885 |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | NEDD8, NAE1, UBA3 | PI4KA 3835/4885PI4K2B 4393/4885PI4K2A 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.